P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo
Latest Information Update: 15 Apr 2024
At a glance
- Drugs CDX 1140 (Primary) ; Odetiglucan (Primary)
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Adverse reactions
- Sponsors HiberCell
Most Recent Events
- 08 Apr 2024 Status changed from active, no longer recruiting to discontinued due to sponsor decision.
- 02 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2023 Planned number of patients changed from 30 to 45.